MiNK Therapeutics, Inc. Common Stock
INKTStock
$10.81−60.41%52W
Market Cap$53.85M
P/E—
Div yield—
Beta0.51
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-21.55%
Price vs S&P 500 (4W)-6.69%
VGM Score36.57
Market Capitalization$53.85M
Earnings Surprise History
Q1 26-0.57est. -0.79
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.13
4.13
4.13
4.13
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
INKTMiNK Therapeutics, Inc. Common Stock | — | — | D | $10.81 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
MiNK Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its manufacturing platform enables scalable production of off-the-shelf cell therapies, with a pipeline of native and engineered iNKT programs.